UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/549,260	12/12/2005	Seiichi Toki	3240-7449US	1642
<sup>24247</sup> TRASK BRITT	7590 12/05/200		EXAMINER	
P.O. BOX 2550	) ITY, UT 84110	ZHENG, LI		
SALI LAKE C	111,01 64110		ART UNIT	PAPER NUMBER
			1638	
			NOTIFICATION DATE	DELIVERY MODE
			12/05/2008	ELECTRONIC

## Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

USPTOMail@traskbritt.com

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)		
10/549,260	TOKI ET AL.		
Examiner	Art Unit		
LI ZHENG	1638		

	LI ZHENG	1638	
The MAILING DATE of this communication appe	ars on the cover sheet with the	correspondence add	ress
THE REPLY FILED 31 October 2008 FAILS TO PLACE THIS A			
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Apperfor Continued Examination (RCE) in compliance with 37 C periods:	the same day as filing a Notice of replies: (1) an amendment, affidaveal (with appeal fee) in compliance	Appeal. To avoid abar vit, or other evidence, we with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	-		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire Is Examiner Note: If box 1 is checked, check either box (a) or (	ater than SIX MONTHS from the mailir b). ONLY CHECK BOX (b) WHEN TH	ng date of the final rejectio	n.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07(1 Extensions of time may be obtained under 37 CFR 1.136(a). The date	•	136(a) and the appropriat	e extension fee
have been filed is the date for purposes of determining the period of ext under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the s set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount hortened statutory period for reply orig	t of the fee. The appropria ginally set in the final Offic	ate extension fee e action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in comp	liance with 37 CFR 41.37 must be	filed within two months	s of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed wi	nsion thereof (37 CFR 41.37(e)), to	o avoid dismissal of the	
AMENDMENTS  3. The proposed amendment(s) filed after a final rejection, by	out prior to the data of filing a brief		
(a) They raise new issues that would require further cor	nsideration and/or search (see NO		cause
(b) They raise the issue of new matter (see NOTE below		aduaina ar aimplifuina tl	na inquan for
<ul><li>(c) ☐ They are not deemed to place the application in beti appeal; and/or</li></ul>	er form for appear by materially re	auding of simplifying tr	ie issues ioi
(d) They present additional claims without canceling a c	orresponding number of finally re	jected claims.	
NOTE: (See 37 CFR 1.116 and 41.33(a)).			
4. The amendments are not in compliance with 37 CFR 1.12		ompliant Amendment (I	PTOL-324).
5. Applicant's reply has overcome the following rejection(s):		Coral Clad and address	( P O
<ol> <li>Newly proposed or amended claim(s) would be all non-allowable claim(s).</li> </ol>	owable if submitted in a separate,	timely filed amendmer	it canceling the
7.  For purposes of appeal, the proposed amendment(s): a) [how the new or amended claims would be rejected is prov The status of the claim(s) is (or will be) as follows:		ill be entered and an ex	xplanation of
Claim(s) allowed:			
Claim(s) objected to:			
Claim(s) rejected: <u>3 and 13</u> . Claim(s) withdrawn from consideration: <u>2, 5-6, 9-10</u> .			
AFFIDAVIT OR OTHER EVIDENCE			
8. The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary	vercome <u>all</u> rejections under appe	al and/or appellant fails	s to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	n of the status of the claims after e	entry is below or attache	ed.
11. The request for reconsideration has been considered but See Continuation Sheet.	does NOT place the application i	n condition for allowand	ce because:
12. Note the attached Information <i>Disclosure Statement</i> (s). (13. Other:	PTO/SB/08) Paper No(s)		
	/Elizabeth F. McElwain Primary Examiner, Art l		
	-		

Continuation of 11. does NOT place the application in condition for allowance because: Claims 3 and 13 remain rejected under 35 U.S.C. 103(c) as being anticipated by Weld et al. (2002, Plant Cell, Tissue and Organ Culture 69:45-54) in view of Clough et al. (1998, The Plant Journal 16:735-743), for the reasons of record stated in the Office action mailed July 31, 2008. Applicants traverse in the paper filed 31 October 2008. Applicants' arguments have been fully considered but were not found persuasive.

Applicants argue that Weld et al. teach against using co-transformation/co-transfection (response, the paragraph bridging pages 4-5). The Office contends that Weld et al. teach that since the Ac transpose gene was not detected in six plants, and Ds excision depends on transposase activity, the transposase source was most likely lost from these plant after transient transposase expression (page 51, 2nd paragraph of the left column). Therefore, Weld et al. teach transient transposase expression. Further, co-transformation/co-transfection is not part of the limitation.

Applicants further argue that the claimed invention provides an unexpected advantage (response, page 5, 2<sup>nd</sup> paragraph). The Office contends that the advantage that Applicants claim is expected from a in planta transformation.